Systematic Investigation on Interactions for HIV Drug Resistance and Cross-Resistance among Protease Inhibitors

Abstract We systematically investigate the interactions for HIV drug resistance and cross-resistance of three protease inhibitors. Using Bayesian probabilistic models, we first detect mutation combinations related to drug resistance in

[1]  P. Donnelly,et al.  Genome-wide strategies for detecting multiple loci that influence complex diseases , 2005, Nature Genetics.

[2]  B. J. Betts,et al.  HIV-1 protease and reverse transcriptase mutation patterns responsible for discordances between genotypic drug resistance interpretation algorithms. , 2003, Journal of acquired immune deficiency syndromes.

[3]  R. Shafer,et al.  Genotypic predictors of human immunodeficiency virus type 1 drug resistance , 2006, Proceedings of the National Academy of Sciences.

[4]  N. Ghoraf.  Reliability formula & limit law of the failure time of “m-consecutive-k-out-of-n:F system” , 2008 .

[5]  J. Mellors,et al.  Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor , 1996, Journal of virology.

[6]  Thomas Lengauer,et al.  Diversity and complexity of HIV-1 drug resistance: A bioinformatics approach to predicting phenotype from genotype , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Jun S. Liu,et al.  Bayesian inference of epistatic interactions in case-control studies , 2007, Nature Genetics.

[8]  Tommy F. Liu,et al.  Web resources for HIV type 1 genotypic-resistance test interpretation. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  Robert W. Shafer,et al.  Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance , 2002, Clinical Microbiology Reviews.

[10]  Bryan Chan,et al.  Human immunodeficiency virus reverse transcriptase and protease sequence database , 2003, Nucleic Acids Res..

[11]  Soo-Yon Rhee,et al.  HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance , 2007, AIDS.

[12]  J. Condra,et al.  In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors , 1995, Nature.

[13]  J. Falloon,et al.  Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites , 1997, Journal of virology.

[14]  J. H. Moore,et al.  Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. , 2001, American journal of human genetics.

[15]  Jing Zhang,et al.  Detecting and understanding combinatorial mutation patterns responsible for HIV drug resistance , 2010, Proceedings of the National Academy of Sciences.

[16]  Huldrych F Günthard,et al.  Update of the drug resistance mutations in HIV-1: Spring 2008. , 2008, Topics in HIV medicine : a publication of the International AIDS Society, USA.